Abstract
Expression of the Escherichia coli enzyme nitroreductase (NTR) in mammalian cells enables them to activate the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954), leading to interstrand DNA cross-linking and apoptosis in both proliferating and quiescent cells. In the work reported here, we used human hepatocellular carcinoma and squamous carcinoma cell lines constitutively expressing NTR to demonstrate that the ntr/CB1954 system results in potent, long-lasting antitumoral effects in mice. We also demonstrate that this enzyme/prodrug combination results in antitumoral effects in vivo when only a minority of tumor cells express the enzyme, using either cells constitutively expressing NTR or ntr gene delivery in situ.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Djeha, A., Hulme, A., Dexter, M. et al. Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954. Cancer Gene Ther 7, 721–731 (2000). https://doi.org/10.1038/sj.cgt.7700171
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700171
Keywords
This article is cited by
-
Versatile cell ablation tools and their applications to study loss of cell functions
Cellular and Molecular Life Sciences (2019)
-
Dual-therapeutic reporter genes fusion for enhanced cancer gene therapy and imaging
Gene Therapy (2013)
-
A mammalianized synthetic nitroreductase gene for high-level expression
BMC Cancer (2009)
-
E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954
British Journal of Cancer (2009)
-
A Phase I/II Clinical Trial in Localized Prostate Cancer of an Adenovirus Expressing Nitroreductase with CB1984
Molecular Therapy (2009)